Covid-19 man­u­fac­tur­ing roundup: In­di­an man­u­fac­tur­er waives vac­cine pro­tec­tions for mi­grants; EMA gives go-ahead for French J&J pro­duc­tion site

Amid fears that mil­lions of mi­grants may not have ac­cess to Covid-19 vac­cines from Co­v­ax fol­low­ing li­a­bil­i­ty fears, the Serum In­sti­tute of In­dia has an­nounced that it will waive its pro­tec­tion from le­gal li­a­bil­i­ties for any As­traZeneca-Ox­ford dos­es it pro­vides to the pro­gram, Reuters re­port­ed Wednes­day.

Co­v­ishield can now be al­lo­cat­ed to the Co­v­ax Hu­man­i­tar­i­an Buffer, a pro­gram de­signed to en­sure that the most vul­ner­a­ble por­tions of pop­u­la­tions, such as con­flict zones or hu­man­i­tar­i­an set­tings that are not able to be reached by gov­ern­ment vac­ci­na­tion cam­paigns, are not left be­hind. Gavi sees it most ef­fec­tive in ar­eas that have been im­pact­ed by state fail­ure or ar­eas con­trolled by groups that are not the gov­ern­ment. Asy­lum seek­ers, refugees, de­tainees, and peo­ple who are state­less are all el­i­gi­ble.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN